fleroxacin has been researched along with Bronchitis in 7 studies
Fleroxacin: A broad-spectrum antimicrobial fluoroquinolone. The drug strongly inhibits the DNA-supercoiling activity of DNA GYRASE.
fleroxacin : A fluoroquinolone antibiotic that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6, 7 and 8 by 2-fluoroethyl, carboxy, fluoro, 4-methylpiperazin-1-yl and fluoro groups, respectively. It is active against many Gram-positive and Gram-negative bacteria.
Bronchitis: Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The pharmacokinetics of fleroxacin, a new broad-spectrum fluoroquinolone, were measured by positron emission tomography (PET) with [18F]fleroxacin in five patients with acute bacterial exacerbations of chronic bronchitis and in five patients with symptomatic, complicated urinary tract infection." | 9.08 | Pharmacokinetics of [18F]fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography. ( Alpert, NM; Babich, JW; Bonab, A; Chodosh, S; Cleeland, R; Correia, JA; Fischman, AJ; Kamitsuka, P; Liu, YY; Livni, E; McGovern, F; Prosser, BL; Rubin, RH, 1996) |
| "The objective of this double-blind, multicenter study was to compare the efficacy and safety of oral fleroxacin, 400 mg once daily for 7 days, with amoxicillin, 500 mg administered every 8 hours for 7 days, in the treatment of acute exacerbation of chronic bronchitis." | 9.07 | Fleroxacin versus amoxicillin in the treatment of acute exacerbation of chronic bronchitis. ( Ulmer, W, 1993) |
| "In a multicenter study the efficacy and safety of oral fleroxacin at 400 mg once a day and amoxicillin at 500 mg three times daily for 7 days were compared for the treatment of patients with acute bacterial exacerbations of chronic bronchitis due to drug-susceptible bacteria." | 9.07 | Efficacy of fleroxacin versus amoxicillin in acute exacerbations of chronic bronchitis. ( Chodosh, S, 1993) |
| "Fleroxacin, administered intravenously at a dosage of 400 mg once a day, was compared with ceftazidime, 0." | 6.67 | Intravenous fleroxacin versus ceftazidime in the treatment of acute nonpneumococcal lower respiratory tract infections. ( Farkas, SA, 1993) |
| "To examine the pharmacokinetics of ciprofloxacin and fleroxacin in plasma and sputum of patients with an acute exacerbation of chronic bronchitis or bronchiectasis following the first dose and again during the third day of treatment." | 5.09 | The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing. ( Begg, EJ; Buttimore, RC; Graham, GG; Neill, AM; Robson, RA; Saunders, DA; Town, GI, 2000) |
| "The pharmacokinetics of fleroxacin, a new broad-spectrum fluoroquinolone, were measured by positron emission tomography (PET) with [18F]fleroxacin in five patients with acute bacterial exacerbations of chronic bronchitis and in five patients with symptomatic, complicated urinary tract infection." | 5.08 | Pharmacokinetics of [18F]fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography. ( Alpert, NM; Babich, JW; Bonab, A; Chodosh, S; Cleeland, R; Correia, JA; Fischman, AJ; Kamitsuka, P; Liu, YY; Livni, E; McGovern, F; Prosser, BL; Rubin, RH, 1996) |
| "The objective of this double-blind, multicenter study was to compare the efficacy and safety of oral fleroxacin, 400 mg once daily for 7 days, with amoxicillin, 500 mg administered every 8 hours for 7 days, in the treatment of acute exacerbation of chronic bronchitis." | 5.07 | Fleroxacin versus amoxicillin in the treatment of acute exacerbation of chronic bronchitis. ( Ulmer, W, 1993) |
| "In a multicenter study the efficacy and safety of oral fleroxacin at 400 mg once a day and amoxicillin at 500 mg three times daily for 7 days were compared for the treatment of patients with acute bacterial exacerbations of chronic bronchitis due to drug-susceptible bacteria." | 5.07 | Efficacy of fleroxacin versus amoxicillin in acute exacerbations of chronic bronchitis. ( Chodosh, S, 1993) |
| "Fleroxacin, administered intravenously at a dosage of 400 mg once a day, was compared with ceftazidime, 0." | 2.67 | Intravenous fleroxacin versus ceftazidime in the treatment of acute nonpneumococcal lower respiratory tract infections. ( Farkas, SA, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (85.71) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Okada, F | 1 |
| Murakami, T | 1 |
| Tokumitsu, Y | 1 |
| Jones, RN | 1 |
| Erwin, ME | 1 |
| Hager, HL | 1 |
| Hohl, PE | 1 |
| Ulmer, W | 1 |
| Chodosh, S | 2 |
| Farkas, SA | 1 |
| Fischman, AJ | 1 |
| Livni, E | 1 |
| Babich, JW | 1 |
| Alpert, NM | 1 |
| Bonab, A | 1 |
| McGovern, F | 1 |
| Kamitsuka, P | 1 |
| Liu, YY | 1 |
| Cleeland, R | 1 |
| Prosser, BL | 1 |
| Correia, JA | 1 |
| Rubin, RH | 1 |
| Begg, EJ | 1 |
| Robson, RA | 1 |
| Saunders, DA | 1 |
| Graham, GG | 1 |
| Buttimore, RC | 1 |
| Neill, AM | 1 |
| Town, GI | 1 |
5 trials available for fleroxacin and Bronchitis
| Article | Year |
|---|---|
Fleroxacin versus amoxicillin in the treatment of acute exacerbation of chronic bronchitis.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Amoxicillin; Bacteria; Bronchitis; Chronic Disease; D | 1993 |
Efficacy of fleroxacin versus amoxicillin in acute exacerbations of chronic bronchitis.
Topics: Acute Disease; Aged; Amoxicillin; Bacteria; Bacterial Infections; Bronchitis; Chronic Disease; Confi | 1993 |
Intravenous fleroxacin versus ceftazidime in the treatment of acute nonpneumococcal lower respiratory tract infections.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Bacteria; Bronchitis; Ceftazidime; Female; Fleroxacin | 1993 |
Pharmacokinetics of [18F]fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography.
Topics: Acute Disease; Adult; Aged; Anti-Infective Agents; Bronchitis; Chronic Disease; Fleroxacin; Fluorine | 1996 |
The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Area Under Curve; Bronchiectasis; Bronchitis; | 2000 |
2 other studies available for fleroxacin and Bronchitis
| Article | Year |
|---|---|
Two cases of fleroxacin-induced insomnia.
Topics: Aged; Bronchitis; Bronchopneumonia; Female; Fleroxacin; Humans; Middle Aged; Sleep Initiation and Ma | 1994 |
Interlaboratory variations of fluoroquinolone susceptibility testing. An international study to validate the quality of microbiology results reported during the fleroxacin clinical trials.
Topics: Bacteria; Bronchitis; Clinical Trials as Topic; Europe; False Positive Reactions; Fleroxacin; Humans | 1993 |